Our data provide insight into the clinicopathological and molecular characteristics of tumors with PIK3R1 dysfunction and may have important implications in the future planning of ovarian cancer therapy with PI3K pathway inhibitors. This evidence concerns the gene PIK3R1 and ovarian carcinoma.